Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

SIRT1 Downregulation Enhances Chemosensitivity and Survival of Adult T-cell Leukemia-Lymphoma Cells by Reducing DNA Double-Strand Repair.

Targeting RAD51 Enhances Chemosensitivity of Adult T‑cell Leukemia‑lymphoma Cells by Reducing DNA Double‑strand Break Repair.

KU70 Inhibition Impairs Both Non-Homologous End Joining and Homologous Recombination DNA Damage Repair Through SHP-1 Induced Dephosphorylation of SIRT1 in Adult T-Cell Leukemia-Lymphoma Cells

SIRT1 Inhibition Impairs Non-Homologous End Joining DNA Damage Repair by Increasing Ku70 Acetylation in Chronic Myeloid Leukemia Cells

Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.

SRT1720 induces SIRT1‐independent cell death in adult T‐cell leukemia/lymphoma

SIRT1 Regulates the Phosphorylation and Degradation of P27 by Deacetylating CDK2 to Promote T-cell Acute Lymphoblastic Leukemia Progression.

GLUT-1 Sirna Enhances Radiosensitization of Laryngeal Cancer Stem Cells Via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis in Vitro and in Vivo.

SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

SIRT3 Increases Cisplatin Sensitivity of Small-Cell Lung Cancer Through Apoptosis.

Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells

AML1-ETO Promotes SIRT1 Expression to Enhance Leukemogenesis of T(8;21) Acute Myeloid Leukemia.

Sirt3 Promoted DNA Damage Repair and Radioresistance Through ATM-Chk2 in Non-small Cell Lung Cancer Cells

Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.

SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.

Impact of SIRT1 silencing on DNA damage repair and chemoradiotherapy resistance in human pancreatic cancer

SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1

Insulin‑like Growth Factor‑1 Receptor Knockdown Enhances Radiosensitivity Via the HIF‑1α Pathway and Attenuates ATM/H2AX/53BP1 DNA Repair Activation in Human Lung Squamous Carcinoma Cells

ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescence by regulating SIRT1/p53/p21 pathway